In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

Ren D, Zhang Z, Zheng X, et al. TLR5 expression marks brain boarder associated macrophages and protects neonatal mice from ...

The study in the European Respiratory Journal used advanced spatial mapping techniques to compare healthy lung tissues and tissues from patients with fatal IPF. The researchers discovered that disease ...

Between the first week of pulmonary rehabilitation and the last recorded session before transplantation, lung transplant ...

This progressive lung disease transforms healthy tissue into stiff, scarred areas making breathing difficult. Learn the warning signs and treatment options.

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting ...

The cells in human bodies are subject to both chemical and mechanical forces. But until recently, scientists have not ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

The Pulmonary Fibrosis Foundation’s 15th annual Broadway Belts for PFF!, held on March 10 at SONY Hall in New York City broke ...